Ipratropium Bromide Aurobindo

Ipratropium bromide, the active ingredient in Ipratropium Bromide Aurobindo, is an anticholinergic bronchodilator presented as an inhalation formulation for inhalation use. It helps open the airways in patients with chronic obstructive pulmonary disease and asthma.

GNH USA supplies Ipratropium Bromide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured products to hospitals, pharmacies and clinics worldwide. Our distribution network adheres to stringent standards to support respiratory care globally.

Ipratropium bromide is an anticholinergic bronchodilator used in the management of obstructive airway diseases. - Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations. - Asthma: provides additional bronchodilation as a maintenance therapy. - Bronchospasm associated with COPD: relieves acute bronchoconstriction episodes.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and related to its anticholinergic activity.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Cough: irritation of the airway. - Throat irritation: discomfort in the throat. - Headache: mild to moderate.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Angioedema: swelling of face, lips or tongue. - Severe allergic reaction: rash, hives, or anaphylaxis.

When prescribing or dispensing ipratropium bromide, consider the following precautions to ensure safe use. - Assess renal function: dose may need adjustment in severe impairment. - Monitor for anticholinergic effects: watch for dry mouth, urinary retention, or blurred vision. - Use caution in narrow‑angle glaucoma: anticholinergic action can increase intra‑ocular pressure. - Avoid in patients with urinary retention: may exacerbate difficulty voiding. - Store at room temperature: keep in original container, protect from moisture and light.

Ipratropium bromide can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Other inhaled anticholinergics (e.g., tiotropium): risk of excessive anticholinergic burden. - Systemic anticholinergic drugs (e.g., atropine): may increase anticholinergic side effects.

Moderate Interactions (Monitor Closely): - Beta2‑agonists (e.g., albuterol): additive bronchodilation may require monitoring. - Theophylline: possible increase in plasma levels; monitor therapeutic range. - Inhaled corticosteroids: no major interaction but monitor overall respiratory status.